Haemonetics/$HAE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Haemonetics
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Ticker
$HAE
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
3,023
ISIN
US4050241003
Website
Haemonetics Metrics
BasicAdvanced
$3.8B
23.62
$3.31
0.37
-
Price and volume
Market cap
$3.8B
Beta
0.37
52-week high
$93.22
52-week low
$55.30
Average daily volume
561K
Financial strength
Current ratio
1.617
Quick ratio
0.883
Long term debt to equity
118.377
Total debt to equity
149.212
Interest coverage (TTM)
6.88%
Profitability
EBITDA (TTM)
355.986
Gross margin (TTM)
57.21%
Net profit margin (TTM)
12.32%
Operating margin (TTM)
17.19%
Effective tax rate (TTM)
20.93%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
6.29%
Return on equity (TTM)
18.83%
Valuation
Price to earnings (TTM)
23.616
Price to revenue (TTM)
2.891
Price to book
4.68
Price to tangible book (TTM)
-13.31
Price to free cash flow (TTM)
27.619
Free cash flow yield (TTM)
3.62%
Free cash flow per share (TTM)
283.03%
Growth
Revenue change (TTM)
3.95%
Earnings per share change (TTM)
44.54%
3-year revenue growth (CAGR)
11.07%
10-year revenue growth (CAGR)
4.10%
3-year earnings per share growth (CAGR)
57.95%
10-year earnings per share growth (CAGR)
26.32%
What the Analysts think about Haemonetics
Analyst ratings (Buy, Hold, Sell) for Haemonetics stock.
Bulls say / Bears say
Haemonetics' Plasma business continues to grow, driven by robust U.S. collection volume and double-digit increases in North America software and Europe disposable revenues. (nasdaq.com)
The company is progressing with the full market release of its new Express Plus technology, enhancing its competitive advantage in plasma collection. (nasdaq.com)
Haemonetics' hospital portfolio is evolving, creating new opportunities for growth and diversification, with each product line holding a leading market position. (nasdaq.com)
Haemonetics' stock hit a 52-week low of $70.1 amid challenges, reflecting market concerns about its financial performance and future prospects. (investing.com)
The company faced a downturn in its stock price following the release of its third-quarter earnings, which showed mixed results and led to lowered fiscal year 2025 growth guidance. (tipranks.com)
Analysts from firms like Raymond James, Mizuho, Barrington, JMP Securities, and BofA have reduced their price targets for Haemonetics, indicating concerns about the company's growth prospects. (tipranks.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Haemonetics Financial Performance
Revenues and expenses
Haemonetics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Haemonetics stock?
Haemonetics (HAE) has a market cap of $3.8B as of July 12, 2025.
What is the P/E ratio for Haemonetics stock?
The price to earnings (P/E) ratio for Haemonetics (HAE) stock is 23.62 as of July 12, 2025.
Does Haemonetics stock pay dividends?
No, Haemonetics (HAE) stock does not pay dividends to its shareholders as of July 12, 2025.
When is the next Haemonetics dividend payment date?
Haemonetics (HAE) stock does not pay dividends to its shareholders.
What is the beta indicator for Haemonetics?
Haemonetics (HAE) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.